Dihoum, Adel

Lang, Chim C.

Mordi, Ify R.

Pearson, Ewan R.

Rena, Graham

English

For a long time, metformin has been the first-line treatment for glycemic control in type 2 diabetes; however, the results of recent cardiovascular outcome trials of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have caused many to question metformin’s position in the guidelines. Although there are several plausible mechanisms by which metformin might have beneficial cardiovascular effects, for example, its anti-inflammatory effects and metabolic properties, and numerous observational data suggesting improved cardiovascular outcomes with metformin use, the main randomized clinical trial data for metformin was published over 20 years ago. Nevertheless, the overwhelming majority of participants in contemporary type 2 diabetes trials were prescribed metformin

University of Dundee Online Publications

Metformin:evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease

https://discovery.dundee.ac.uk/ws/files/99989447/Metformin_evidence_from_preclinical_and_clinical_studies_for_potential_novel_applications_in_cardiovascular_disease.pdf

Metformin:Evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease

Abstract

Similar works

Full text

Available Versions

University of Dundee Online Publications

University of Dundee Online Publications